Ukrainian Journal of Perinatology and Pediatrics. 2021.4(88): 60-65; doi 10.15574/PP.2021.88.60
Kondratiuk V. K.^1,2, Horban N. Ie.², Koblosh N. D.^2
1Shupyk National Healthcare University of Ukraine, Kyiv
²SI «Institute of Pediatrics, Obstetrics and Gynecology named after academician O.M. Lukyanova of the NAMS of Ukraine», Kyiv

For citation: Kondratiuk VK, Horban NIe, Koblosh ND. (2021). Modern strategies of prophylaxis of chasse of cervix of the uterus. Realities of present time (literature review). Ukrainian Journal of Perinatology and Pediatrics. 4(88): 60–65. doi 10.15574/PP.2021.88.60.
Article received: Aug 16, 2021. Accepted for publication: Dec 07, 2021.

The role of human papilloma virus in the development of cervical cancer and other diseases of the anogenital area is proven and well known. Despite this, there is an annual increase in the incidence of cervical cancer. Cervical cancer screening is a population-based set of organizational and medical measures aimed at early detection of precancerous and tumorous diseases of the cervix and to reduce mortality in this group of patients. After the discovery of the viral nature of cervical cancer and the introduction of a number of methods to detect human papilloma virus — HPV testing has become important. Diagnosis of cancer in the early stages increases the likelihood of an effective response to organ-sparing surgical treatment, increases the patient's chances of survival and allows the use of less expensive treatments. HPV screening is sensitive not only to the detection of precancerous diseases, but also significantly reduces the incidence and mortality from cervical cancer, which is the main indicator of its effectiveness. However, specific antiviral treatments for human papillomavirus have not been developed, and vaccination is the only effective way to prevent cervical cancer and other associated diseases. The prevalence of papillomavirus infection has increased more than 10-fold in the last decade. One of the key points in cervical cancer prevention is vaccination. Routine HPV vaccination is recommended at the age of 11–12 years and can also be given from the age of 9; vaccination is recommended for all people under the age of 26 who did not pass the procedure on time; when vaccinating persons <15 years of age, it is recommended to administer the vaccine according to a 2-dose schedule. Individuals with human immunodeficiency virus and other immunosuppressed conditions should receive a 3-dose vaccination. In countries where human papillomavirus vaccination is widely used, the incidence rates show a decrease in the incidence of cervical cancer. The coronavirus pandemic threatens to disrupt vaccination against human viral papilloma in low- and middle-income countries, which negatively affects the strategy to eliminate cervical cancer. The WHO Global Response to the COVID Pandemic has been a catalyst for innovation and adaptation at the health system level that can be used to improve access to and dissemination of information in the context of HPV vaccination and cervical cancer screening.
No conflict of interest was declared by the authors.
Key words: human papilloma virus, cervical cancer, vaccination, cornavirus disease.

REFERENСES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68: 6. https://doi.org/10.3322/caac.21492; PMid:30207593

2. Brisson M, Kim JJ, Canfell K. (2020, Feb 22). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries Lancet. 395 (10224): 575-590. https://doi.org/10.1016/S0140-6736(20)30068-4

3. Bruni L, Albero G, Serrano B, Mena M, Gomez D, Munoz J, Bosch FX, Sanjose de S. (2018, Feb). ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre) Human Papillomavirus and Related Diseases Report in EUROPE. Summary Report. URL: http://www.hpvcentre.net.

4. Canfell K, Kim JJ, Brisson M. (2020, Feb 22). Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 395 (10224): 591-603. https://doi.org/10.1016/S0140-6736(20)30157-4

5. Centers for Disease Control and Prevention. (2020). Cancers associated with human papillomavirus. United States – 2012-2016.

6. Chee Kai Chan, Gulzhanat Aimagambetova, Talshyn Ukybassova. (2019, Oct 10). Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination – Review of Current Perspectives. J Oncol. https://doi.org/10.1155/2019/3257939; PMid:31687023 PMCid:PMC6811952

7. Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. (2018, Dec). Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV TestingViruses. 10 (12): 729. https://doi.org/10.3390/v10120729; PMid:30572620 PMCid:PMC6315375

8. De Martel C, Plummer M, Vignat J, Franceschi S. (2017). Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 141: 664-670. https://doi.org/10.1002/ijc.30716; PMid:28369882 PMCid:PMC5520228

9. Della Fera AN, Warburton A, Coursey TL. (2021, Feb 20). Persistent Human Papillomavirus Infection Viruses. 13 (2): 321. https://doi.org/10.3390/v13020321; PMid:33672465 PMCid:PMC7923415

10. Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. (2015, Mar). Human papillomavirus molecular biology and disease association. Rev Med Virol. 25 (1): 2-23. https://doi.org/10.1002/rmv.1822; PMid:25752814 PMCid:PMC5024016

11. Drolet M et al. (2015). Population$level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 15: 565-580.

12. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M et al. (2020). Global Cancer Observatory: Cancer Today. Lyon: International Agency for Research on Cancer. URL: https://gco.iarc.fr/today.

13. Future II Study Group. (2007). Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. New England Journal of Medicine. 356 (19): 1915-1927. https://doi.org/10.1056/NEJMoa061741; PMid:17494925

14. Garland SM et al. (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 356 (19): 1928-1943. https://doi.org/10.1056/NEJMoa061760; PMid:17494926

15. Garland SM et al. (2007). Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New England Journal of Medicine. 356 (19): 1928-1943. https://doi.org/10.1056/NEJMoa061760; PMid:17494926

16. Garland SM, Paavonen J, Jaisamrarn U et al. (2016). HPV PATRICIA Study Group, Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high-grade cervicalintraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial. Int J Cancer. 139 (12): 2812-2826. https://doi.org/10.1002/ijc.30391; PMid:27541373 PMCid:PMC5412942

17. GHDx. (2021). GBD results tool. Seattle (WA): Institute for Health Metrics. University of Washington. URL: http://ghdx.healthdata.org/gbd-results-tool.

18. Leodolter S, Hernandez-Avila M et al. (2007). Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 369: 1693-1702. https://doi.org/10.1016/S0140-6736(07)60777-6

19. Martel de C, Georges D, Bray F, Ferlay J, Clifford GM. (2020). Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 8 (2): e180-e190. https://doi.org/10.1016/S2214-109X(19)30488-7

20. McBride AA. (2017). Mechanisms and strategies of papillomavirus replication. Biol Chem. 398: 919-927. https://doi.org/10.1515/hsz-2017-0113; PMid:28315855

21. Mezei AK, Armstrong HL, Pedersen HN et al. (2017). Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review. Int J Cancer. 141 (3): 437-446. https://doi.org/10.1002/ijc.30695; PMid:28297074

22. Ogilvie GS, van Niekerk D, Krajden M et al. (2018). Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 320 (1): 43-52. https://doi.org/10.1001/jama.2018.7464; PMid:29971397 PMCid:PMC6583046

23. PATH. (2019, November). Global HPV Vaccine Introduction Overview: projected and current national introductions, demonstration/pilot projects, gender$neutral vaccination programs, and global HPV vaccine introduction maps (2006-2022). URL: https://www.path.org/resources/global-hpv-vaccine-introduction-overview/.

24. Prilepskaya VN, Gusakov KI, Nazarova NM. (2019). Vaccination as an effective method of prevention for cervical diseases associated with human papillomavirus (literature review). Gynecology. 21 (2): 23-27. https://doi.org/10.26442/20795696.2019.2.190396

25. Riley L. (2019). Monitoring cervical cancer: screening and treatment coverage. Presentation using the WHO Steps Survey (cervical cancer screening) 2019. URL: https://apps.who.int/iris/handle/10665/275391.

26. Schiffman M, Doorbar J, Wentzensen N, Sanjose de S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. (2016). Carcinogenic human papillomavirus infection. Nat Rev Dis Prim. 2: 16086. https://doi.org/10.1038/nrdp.2016.86; PMid:27905473

27. Smith MA, Gertig D, Hall M et al. (2016). Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC Health Serv Res. 16 (1): 147. https://doi.org/10.1186/s12913-016-1375-9; PMid:27112193 PMCid:PMC4845438

28. Swedish KA, Factor SH, Goldstone SE. (2012). Prevention of recurrent highgrade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 54 (7): 891-898. https://doi.org/10.1093/cid/cir1036; PMid:22291111

29. The Lancet. (2020, Feb 1). Eliminating cervical cancer. Editorial. Lancet. 395 (10221): 312. https://doi.org/10.1016/S0140-6736(20)30247-6

30. Toh ZQ, Kosasih J, Russell FM. (2019). Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus Infect Drug Resist. 12: 1951-1967. https://doi.org/10.2147/IDR.S178381; PMid:31308715 PMCid:PMC6613616

31. WHO. (2005). Expanded Programme on Immunization. Vaccine. Adding a vaccine to a national immunization programme: decision and implementation. Geneva. URL: http://www.who.int/vaccines-documents/DocsPDF05/777_screen.pdf.

32. Wild CP, Weiderpass E, Stewart BW. (2020). World Cancer Report: Cancer Research for Cancer Prevention. Lyon: International Agency for Research on Cancer.

33. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. (2021, Jul 23). Sexually Transmitted Infections Treatment Guidelines, 2021. Recomm Rep. 70 (4): 1-187. https://doi.org/10.15585/mmwr.rr7004a1; PMid:34292926 PMCid:PMC8344968

34. World Health Organization. (2018). Comprehensive Cervical Cancer Control: A Guide to Essential Practice. 2nd ed Geneva, Switzerland: WHO Press.

35. World Health Organization. (2020). Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2019 global survey. Geneva.